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LETTERS TO THE EDITOR
Single-Nucleotide Polymorphism rs498055
on Chromosome 10q24 Is Not Associated
with Alzheimer Disease in Two Independent
Family Samples
To the Editor: In the January issue of the American Journal
of Human Genetics, Grupe and colleagues1 published evi-
dence suggesting genetic association between SNP rs498055
on chromosome 10q24, located in a putative homologue
of ribosomal protein S3a (RPS3A [MIM 180478]), and risk
for Alzheimer disease (AD [MIM 104300]) in four of six
independent case-control samples. The authors reached
this conclusion after testing nearly 1,400 SNPs, using an
exploratory case-control sample, followed by assessments
of a number of independent data sets of different size,
origin, and ascertainment. Although three of the replica-
tion samples showed significant risk effects for the G allele
of rs498055, this effect was not confirmed in two smaller
series of neuropathologically confirmed AD cases and con-
trols. None of the other 68 “hits” uncovered in the first
pass received the same degree of consistent replication as
did rs498055. Overall, the effect of the putative risk allele
was modest (yielding odds ratios [ORs] between ∼1.3 and
1.4) and—according to the authors’ conclusion—likely re-
flects linkage disequilibrium (LD) with another genetic
variant nearby. Here, we have set out to independently
assess the association between rs498055 and AD risk in
two large and carefully characterized samples of AD-af-
fected families comprising nearly 1,900 subjects from 654
pedigrees. However, in contrast to the findings of Grupe
and colleagues, we observed no evidence of association
between rs498055 and AD in any of our analyses.
Using high-efficiency fluorescence polarization (HEFP)
technology, we genotyped this SNP in two family-based
AD samples: (1) 1,439 subjects from 437 multiplex AD-
affected families recruited as part of the National Institute
of Mental Health (NIMH) Genetics Initiative AD Study
Sample (average age at onset [SD] of affected individuals
was years) and (2) 489 subjects from 217 in-72.4  7.7
dependent families, mostly consisting of discordant sib-
ships, recruited as part of the Consortium on Alzheimer’s
Genetics (CAG) (average age at onset was years).71.2  9.1
These samples, as well as the genotyping procedures, are
described in detail in the work of Bertram et al.2; PCR and
HEFP primer sequences for rs498055 are available on re-
quest. Average genotyping efficiency across both samples
was 98.4%, with a genotyping error rate !1% (on the basis
of ∼10% duplicated samples). Power analyses (fig. 1) in
the combined sample showed that, at a disease-allele fre-
quency of 0.47 (i.e., the average frequency of the G allele
in U.S. controls reported by Grupe et al.) and ,a p .05
power was 64% for an OR of 1.3 and was 83% for an OR
of 1.4 (see fig. 1 for more details). Naturally, power was
lower for the two samples considered separately, but it was
still 40%–60% for the NIMH sample alone, comparable to
the power of the replication samples in the study by Grupe
et al.
In contrast to the findings of Grupe et al., we did not
observe any significant evidence of association between
rs498055 and AD risk, neither in the two samples indi-
vidually nor after combining both data sets (table 1), over-
all or when stratified by age at onset (with age 65 years
as cutoff) or apolipoprotein E (APOE [MIM 107741]) 4-
carrier status. Interestingly, and in contrast to the over-
transmission of the G allele noted by Grupe et al., in our
two samples, this allele was generally undertransmitted
to affected individuals, which approached statistical sig-
nificance in two of our stratified analyses in the combined
sample ( in “late-onset” families, and inP p .09 P p .06
“APOE 4-positive” families [table 1]). Finally, we also
tested for association between rs498055 and age at onset
of AD (age at last examination of unaffected individuals),
using FBAT-LOGRANK, FBAT-Wilcoxon, and FBAT-Flem-
ington-Harrington3,4 in the unstratified samples. However,
none of these tests showed even marginally significant P
values (data not shown). Since quantitative trait analyses
are expected to be more powerful than analyses of binary
traits if the underlying association is true,3 these results
strengthen our overall negative conclusion.
Our study is the first to independently assess the poten-
tial association between rs498055 and AD that had emerged
from a semisystematic screen of 1,397 SNPs on chromo-
some 10.1 The fact that we failed to replicate the previous
findings is noteworthy for several reasons. First, rs498055
is located within the chromosome 10q24 linkage peak re-
ported elsewhere for this collection of NIMH families.5
Thus, our sample should be particularly well suited to de-
tect disease associations underlying this linkage signal.
Second, our study is the first to analyze this SNP with use
of family-based methodologies in which affected subjects
are compared with related unaffected subjects from the
same family. Results from such analyses are more robust
to bias due to population admixture or other sources of
skewed genotype distributions in cases or controls; this is
of particular note, given the differences in allele frequen-
cies reported for the two control populations from the St.
Louis area in the work of Grupe et al. (see below). Despite
the strengths of our approach, it is possible that we have
missed a putative risk effect at rs498055 because of insuf-
ficient power, especially when aiming to detect minor ef-
fects with ORs of 1.3 (fig. 1). However, the differences
between our findings and those of Grupe et al. are unlikely
to result from lack of power alone, since we see under-
rather than overtransmission of the G allele in both sam-
ples. It is unclear whether these discrepancies are caused
by chance or by differential patterns of LD across the var-
ious samples.
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Figure 1. Power to detect a range of effect sizes in the family samples analyzed. Power estimates were done with PBAT (v3.1).12
Estimates are based on approximation and are calculated for an additive disease model based on parameters published by Grupe et al.1
(i.e., disease-allele frequency of 0.47 and OR 1.2–1.6), with the exception of disease prevalence, which was set to 10%. Although the
precise prevalence of AD is unknown and difficult to estimate, power does not change appreciably when prevalence is varied from 5%
to 15% (data not shown). ORs are for heterozygous carriers of the disease allele versus homozygous noncarriers. Families were modeled
after the observed pedigree structure for each sample, with both parents set as “missing.” Note that PBAT can currently handle a
maximum offspring number of only four; however, 68 (16%) of NIMH pedigrees actually have more than four genotyped and phenotyped
offspring, so that the power for “NIMH” and “NIMHCAG” is likely to be underestimated (see the PBAT Web site for more details).
The long arm of chromosome 10 has been a focus of
work for many AD genetics laboratories since the discovery
of significant linkage with AD phenotypes by three inde-
pendent groups, including ours (AD6 [MIM 605526]).5–7
These publications were followed by two additional stud-
ies suggesting the presence of an AD risk and/or age-at-
onset–modifying gene on this chromosome.8,9 Although
nearly 30 positional candidate genes have since been as-
sessed as potential AD risk factors underlying these linkage
signals and several positive association findings have been
published, no gene has received consistent support from
independent follow-up studies,10 and none shows evidence
of conclusive and significant summary effects in system-
atic meta-analyses of all published and available genotype
data (AlzGene).
Unfortunately, the present failure to replicate the prom-
ising results of Grupe and colleagues is consistent with
this overall pattern. There are several possible reasons for
the differences between our findings and theirs. First, the
difference might be due to chance, because the initial find-
ing is a false-positive result. The 69 hits among 1,397 SNPs
in the exploratory data set is close to the expected value
by chance alone, as is the confirmation of 5 of these 69
signals in at least one of the two direct follow-up samples.
However, we agree with the authors that a significant over-
representation of the same allele in three of five confir-
mation samples, as observed for rs498055, may be unlikely
to occur by chance alone. Second, the difference might
have arisen by chance because our finding is a false-neg-
ative result. Although this is possible, it should be noted
that our sample is as large or larger than many replication
samples in the field. In addition, the difference is unlikely
to result from insufficient power alone, because the puta-
tive risk allele, if anything, is undertransmitted in our sam-
ples. Third, the differences may relate to our use of family-
based methods, which are more robust to bias due to pop-
ulation admixture. Although the degree to which admix-
ture may lead to spurious association findings in case-
control samples is controversial,11 the issue is a concern
here, given the marked difference in allele frequencies
across the two independent Washington University con-
trol samples (47% for the case-control sample—similar to
the other U.S. control sample—and 44% for the controls
used in comparison with the linkage sample), a difference
substantial enough that the allelic association between
rs498055 and AD in the linkage sample (49.8% risk-allele
frequency) would not have been significant had the other
Washington University control set (or the University of
California–San Diego controls) been used. Finally, the dif-
ferences across studies may be due to differences in pat-
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NIMH .519 123 1.096 .27
CAG .504 84 .194 .85
Combined .514 207 1.001 .32
Families with late-onset disease:
NIMH .537 81 1.541 .12
CAG .531 66 .808 .42
Combined .535 147 1.703 .09
APOE 4-positive families:
NIMH .494 107 1.488 .14
CAG .515 31 1.380 .17
Combined .499 138 1.929 .06
NOTE.—Association tests were performed using FBAT (v1.5.5) with an additive transmission
model, the empirical variance function, and an equal-weight offset correction for affected and
unaffected individuals (see the FBAT Web site for more details).
a Families were classified as “late onset” when all sampled affected individuals had age at
onset of 165 years and were classified as “APOE 4 positive” when at least one affected individual
per family carried the 4 allele. The smaller strata of remaining families (i.e., those displaying
an earlier age at onset or those in which none of the affected individuals carried an 4 allele)
also failed to show evidence of significant association (data not shown).
b For the G allele of rs498055, which was reported as the putative risk allele by Grupe et al.1
(positive values indicate overtransmission to affected individuals). Note that the direction of
transmission is consistent for both family samples analyzed here and is opposite to that seen
in the previous publication.1
terns of LD across the various samples, which are impos-
sible to assess as long as the precise nature of the putative
risk allele at this locus remains unknown.
Clearly, additional analyses of sufficiently powered
and independent samples are needed to assert whether
rs498055, or a polymorphism in LD with it, makes a rel-
evant contribution to AD risk. At least in the two family
samples investigated here—one of which shows linkage
to the same chromosomal interval as rs498055—this SNP
is not a major determinant of AD risk.
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Reply to Bertram et al.
To the Editor: The study by Bertram and colleagues (in
this issue)1 failed to replicate, in two family-based sample
sets, the association of rs498055 with Alzheimer disease
(AD [MIM 104300]) that we observed in four large, well-
characterized case-control sample sets.2 Although the re-
sult is disappointing, there are several differences between
the studies that may have contributed to these discrepant
findings. First, there are significant differences in the study
designs. Bertram et al. used two family-based sample sets
that included subjects with both early- and late-onset
AD (e.g., 320 families with late-onset AD and 117 families
with early/mixed-onset in the National Institute of Mental
Health [NIMH] sample set) of different ethnicities (94%
white; 6% others),3 which resulted in 147 informative
families with late-onset AD for both sample sets com-
bined. The characterization of their unaffected controls
was based on self-assessment or a telephone interview, a
procedure sufficient when “unaffecteds” are used solely
to determine phase in linkage studies, but likely to sig-
nificantly impact power in association studies, especially
when familial loading is high, as it is in the sample of
Bertram et al. Indeed, the authors acknowledge this in one
of their previous publications by pointing out that the
characterization of controls “may miss some mild cases of
dementia” and lead “to a decrease in power.”3 In contrast,
our study included only clinically evaluated, late-onset
cases and nondemented controls of white origin. Second,
the use of a family-based sample that was ascertained on
the basis of multiple affected relatives is likely to partic-
ularly adversely impact power to detect a risk allele of
relatively high frequency and small effect size, such as
rs498055. Under these circumstances, the allele frequency
in unaffected relatives also increases,4 with consequent
loss of power in comparison with case-control studies such
as our own. To investigate this more fully, we compared
the allele frequencies for a known genetic risk factor for
AD, apolipoprotein E (APOE [MIM 107741]), and for the
putative risk factor under debate, rs498055, in our com-
bined case-control series and in the NIMH linkage families
used by us in the study described by Myers et al.5 In this
context, it is worth noting that 355 of 372 individuals
from the linkage sample–derived cases in our recent pub-
lication overlap with affected individuals in the NIMH
family sample set described by Bertram et al. For the com-
parison, we identified the subgroup of NIMH families with
genotypes for at least one unaffected and one affected
individual and then selected at random one unaffected
and one affected individual from each of these families.
Table 1 illustrates clearly that the frequency of the APOE4
allele is substantially higher in unaffected individuals from
the linkage families than in unaffected individuals from
the case-control series (30.4% vs. 12.5%) and that, although
the APOE4 allele frequency is highest in the linkage cases,
the difference between the unrelated cases and controls
is much greater than that between familial cases and re-
lated controls (35.6% vs. 12.5% compared with 42.8% vs.
30.4%). As a result, the odds ratio (OR) for the APOE4 allele
in the case-control series is 3.8, compared with only 1.7
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Table 1. LD between SERPINE2 SNPs Expressed as r2
SNP
r2 for SNP
rs1438831 rs920251 rs6747096a rs3795879
rs920251 .952 (1.0) … … …
rs6747096a .140 .148 … …
rs3795879a .140 (.145) .145 (.145) .964 …
ss49785625a .020 .023 .054 .055
NOTE.—The r2 values in parentheses are values obtained from HapMap
and compared with our own data in controls. ss49785625 and rs6747096
are not in HapMap.
a SNP reported by DeMeo et al.1 to be associated with disease in both
family and case-control cohorts.
for the family-based samples. Similarly for rs498055, the
difference in frequencies between the cases and controls
is greater for the unrelated samples than for the linkage
families (table 1). Thus, the failure of Bertram et al. to
replicate our results does not necessarily indicate that the
original association was a false-positive result. We concur
with Bertram et al. that the significant association of
rs498055 in four of six samples “may be unlikely to occur
by chance”1(p181) (in this issue). However, it is possible that
our initial study provided an overestimate of the allelic
OR for rs498055. If this were true and the OR were !1.3,
then the study by Bertram et al. would clearly be under-
powered. Further replication in well-characterized sample
sets is required to assess whether the association is gen-
uine. Ideally, this should be done with large case-control
sample sets, to achieve maximum power. For this partic-
ular marker, we estimate that 360 cases and 360 controls
are needed to achieve 80% power in a replication study
(one-sided ), assuming an allelic OR of 1.3 anda p .05
a risk-allele frequency of 45.6%. A meta-analysis of all
studies should then be performed to determine whether
rs498055 is associated with late-onset AD. In addition, it
might be interesting to test the other reported significant
markers from this region in additional sample sets.
ANDREW GRUPE, YONGHONG LI, CHARLES ROWLAND,
TONY HINRICHS, PETER HOLMANS, JOHN HARDY,
MICHAEL O’DONOVAN, MICHAEL J. OWEN,
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The SERPINE2 Gene and Chronic Obstructive
Pulmonary Disease
To the Editor: In the February 2006 issue of the Journal,
DeMeo et al.1 identified SERPINE2 as a positional candi-
date gene for susceptibility to chronic obstructive pul-
monary disease (COPD [MIM 606963]) and reported on
the association of polymorphic variants of this gene with
early-onset disease in a family-based study and with severe
disease in a case-control study. With early prior infor-
mation provided by the authors, we have independently
tested for an association of the SERPINE2 gene with COPD
in the largest case-control study reported to date. Our
study consists of 1,018 COPD cases and 911 controls pro-
spectively recruited from six European centers. We have
provided details about the patients elsewhere.2 The study
population was screened for genotypes at the Medical Re-
search Council (United Kingdom) Gene Services Unit for
five SNPs (table 1) in the SERPINE2 gene. All the SNPs
evaluated were reported in the study by DeMeo et al. as
associated with disease, with three of the five associated
with disease in both the family and case-control study
cohorts they assessed.
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Table 2. SERPINE2 Genotype and Allele







C T CC CT TT
rs1438831:
COPD case .66 .34 .43 .45 .12
Control .66 .34 .43 .46 .11
A G AA AG GG
rs920251:
COPD case .35 .65 .13 .45 .42
Control .35 .65 .12 .46 .42
A G AA AG GG
rs6747096:
COPD case .79 .21 .61 .35 .04
Control .79 .21 .63 .33 .04
C T CC CT TT
rs3795879:
COPD case .78 .22 .60 .36 .05
Control .79 .21 .62 .33 .05
A G AA AG GG
ss49785625:
COPD case .54 .46 .30 .48 .22
Control .53 .47 .29 .48 .23
We examined linkage disequilibrium (LD) between the
SNPs (table 1) and evaluated SNP and haplotype associa-
tions as described elsewhere.2 DeMeo et al. did not report
specific LD values between SNPs or noncontiguous SNPs
contributing to haplotypes. SNPs and genotype frequen-
cies in the study population are shown in table 2. We
found no significant deviation from Hardy-Weinberg equi-
librium in frequencies for any of the SNPs.
We found no association between any of the SERPINE2
SNPs and disease, in examining both the allelic and ge-
notype distributions, although our study was well pow-
ered to detect associations of the magnitude observed by
DeMeo et al., and we would have expected to see these
frequency differences with the SNPs that we studied. We
also failed to find a relationship between any haplotypes
of these SNPs and disease (data not shown). It was of in-
terest that the allele and genotype frequencies observed
in our control and patient groups were virtually identical
to those observed in control subjects by DeMeo et al.,
indicating a common distribution of SERPINE2 variants
in the European and North American populations studied.
Our previous study has also shown that there is no evi-
dence of population stratification in our sample.
Patients evaluated in both the family-based and case-
control studies reported by DeMeo et al. represent a severe
subset of the disease spectrum. To determine whether the
association with SERPINE2 noted by DeMeo et al. was re-
lated to disease severity, we also analyzed SNP allele and
genotype frequencies in the subgroup of our patients with
forced expiratory volume at 1 s 45% ( ), a groupn p 388
that represents severe disease, but we failed to observe any
association.
Our inability to replicate the observations of DeMeo et
al. in a more highly powered case-control study may be
related to differences in the disease phenotype of the pa-
tients studied, because our patients included those with
and without emphysema. The possibility, however, that
the associations reported by DeMeo et al. represent false-
positive results must also be considered. In this respect, it
is of note that, in the study by DeMeo et al., different
associations were reported for SNPs that are in linkage
disequilibrium with one another. For example, rs3795879
and rs3795877 have an r2 value of 1 in HapMap, yet
different associations with quantitative spirometric phe-
notypes were reported for the family study. Similarly,
rs1438831 and rs920251 are in complete LD, with an r2
value of 1 in HapMap and 0.95 in our study; however, in
DeMeo et al.’s case-control study, the allele and genotype
frequencies of rs920251 were found to be significantly as-
sociated with disease (P values of 0.015 and 0.011, re-
spectively), whereas no similar association was observed
for rs1438831. In both instances, the almost complete
linkage between these pairs of SNPs would be expected to
result in similar associations.
These results underline the importance of replication in
other large independent studies before SERPINE2 can be
unequivocally assigned as a candidate gene for COPD. It
is becoming apparent that, to detect modest genetic effects
for complex diseases, several independent studies may be
required and the data may need to be subjected to meta-
analysis. For example, this approach has been used to
study Alzheimer disease (see Alzheimer’s Association Web
site). Similar approaches need to be adopted for COPD. It
would also be helpful to have similar criteria adapted for
phenotypic selection and to plan prospective studies on
this basis.
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Reply to Chappell et al.
To The Editor: We appreciate the efforts of Chappell and
colleagues1 to replicate our SERPINE2 findings. We iden-
tified SERPINE2 as a candidate gene for chronic obstructive
pulmonary disease (COPD [MIM 606963]) on the basis of
our gene-expression results (in both murine and human
lung) and our genetic association analysis results in two
study populations. Chappell et al. found no evidence for
association of five SERPINE2 SNPs with COPD in their case-
control study. As in many complex-disease genetic asso-
ciation studies in general, and in previous COPD ge-
netic association studies in particular,2 the results are
inconsistent.
There are many potential explanations for these incon-
sistent results, including population stratification, genetic
heterogeneity, false-positive and/or false-negative results,
differences in the number of SNPs genotyped, and phe-
notypic heterogeneity.3 In comparing the results of our
two research groups for association analysis of SERPINE2
SNPs with COPD, phenotypic heterogeneity is of partic-
ular importance. COPD is a syndrome composed of both
emphysema and airway disease, with variable contribu-
tions of these processes in different individuals with
COPD. Review of chest CT scans of probands from the
Boston Early-Onset COPD Study—the population in
which we performed family-based association analysis of
COPD-related phenotypes—revealed that the vast major-
ity of these probands had emphysema.4 Moreover, the
COPD cases in our case-control replication population
were clearly selected for emphysema as part of the Na-
tional Emphysema Treatment Trial (NETT). In addition,
the Boston Early-Onset COPD Study probands and the
NETT cases had very severe COPD. Thus, our test and
replication populations were severely affected with COPD,
typically with a substantial degree of emphysema. As
noted by Chappell et al., our cases represent “a severe
subset of the disease spectrum,”1(p185) and their cases rep-
resent a broader spectrum of severity, including individ-
uals with and without emphysema. The differences in
disease severity and emphysema may be important con-
tributors to their nonreplication of our association find-
ings. Also of note, although Chappell et al. genotyped five
SNPs in SERPINE2, they did not genotype several other
SNPs for which we observed replicated associations and
LOD score reduction in conditional linkage models.
Chappell et al. also comment about apparently incon-
sistent association results in our family-based and case-
control association analyses among SNPs in tight linkage
disequilibrium (LD). Modest differences in the statistical
significance of the association analysis results were noted
for several SNPs that are in strong but not complete LD
in our study populations. There are reasonable explana-
tions for these modest differences. (1) The SNP pairs men-
tioned are not in complete LD; in our combined case-
control cohort, the r2 values were 0.93 for rs3795879 and
rs3795877 and 0.91 for rs1438831 and rs920251. (2) De-
spite excellent genotype completion rates, there were
slight differences in missing data between these SNP pairs.
Of note, these were not the only SERPINE2 SNPs signifi-
cantly associated with COPD-related phenotypes in our
study; we observed 18 significantly associated SERPINE2
SNPs in the family-based association analysis and 7 sig-
nificantly associated SNPs in the case-control analysis.
We fully agree with Chappell et al. that replication of
significant associations is essential—which is why we in-
cluded in our article the replication of our family-based
association analysis results in a separate case-control
study. This is also the reason why we provided early access
to significantly associated SNPs to the Chappell and Kal-
sheker group.
Is SERPINE2 a confirmed COPD susceptibility gene? Cer-
tainly not. Before the impact of SERPINE2 on COPD sus-
ceptibility is fully known, more genetic association studies
as well as functional studies will be needed. However, we
contend that SERPINE2 remains a valid COPD candidate
gene. Finally, we agree with Chappell et al. that agreement
on phenotypic definitions and collaboration between re-
www.ajhg.org The American Journal of Human Genetics Volume 79 July 2006 187
search groups are crucial for the future of genetic studies
of COPD and other complex diseases.
Web Resources
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for COPD)
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